EDMONTON, March 29 /CNW/ - Ceapro Inc. (TSX-V: CZO) today announced the appointment of two officers; Shawn McMillan is appointed Chief Financial Officer and David Fielder is appointed Vice President Scientific Affairs. Dr. Mark Redmond, Ceapro's President and CEO stated, "Ceapro is delighted to announce the appointment of two such highly qualified and talented individuals as officers of the corporation. The critical role that each of these individuals plays in Ceapro today makes these appointments appropriate and as we plan for Ceapro's future Shawn and David will play important roles in corporate development and succession strategy" Shawn McMillan, B.Comm., CA since joining Ceapro in 2005 in the position of Corporate Secretary and Financial Controller, Shawn has been responsible for financial planning and reporting, strategy support, productivity and accounting processes, as well as compliance and risk management. Under his guidance Ceapro has implemented policies in compliance with the highest North American standards for public companies with respect to financial reporting, audit, and corporate governance. Shawn is a native Albertan and graduate from the University of Alberta. David Fielder, M.Sc. joined Ceapro in 1996 and has played a major role in the discovery, conception, and commercialization of all of Ceapro's core technology. For the last five years, David has directed the Company's operations at the Leduc manufacturing plant. He has also played an increasingly significant role in technical marketing and customer recruitment as Ceapro expands its markets. David is a graduate of the Carleton University with a specialized degree in natural products chemistry. About Ceapro Inc. Ceapro Inc is a growth stage biotechnology company. Ceapro's core technology is the extraction of functional, active ingredients from plants for sale to the personal care and healthcare markets. We also manufacture our own line of products for human and animal health, as well as providing screening and diagnostic services using our proprietary CeaProve(R) technology. Ceapro shares trade on the TSX Venture Exchange under the symbol CZO. To learn more about Ceapro, log on to our website at www.ceapro.com. Shares Outstanding: 37,098,670, Recent Close: $0.27 The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the accuracy of this news release. This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements. Although the Company believes that the forward- looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. %SEDAR: 00010110E
Ceapro announces Corporate Officer appointments
Earlier from Ceapro
- Ceapro successfully closes $1.3 million financing
- Ceapro announces 2005 third quarter financial results
- Ceapro to present CeaProve(TM) at Canadian Diabetes Association conference
- Ceapro announces adoption of CeaProve(TM) in global Glycemic Index study
- Ceapro announces 2005 second quarter financial results
Later from Ceapro
- Ceapro announces 2005 financial results
- Ceapro receives prestigious international award
- Ceapro announces 2006 first quarter financial results
- Ceapro Inc. - Annual General Meeting Webcast - June 1, 2006
- Ceapro named on Profit 100 list of Canada's fastest-growing companies
Follow Ceapro into a list and get an email when it puts out news.
Follow Ceapro